A Study of AK-1286 in Patients With Advanced Solid Tumors | NCT06779045

NCT06779045

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
AK-1286	Experimental	After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once or twice daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.	Drug: AK-1286

Interventions

Name	Type	Description	Arm Group Labels	Other Names
AK-1286	Drug	Cohort 1: 1 mg/d QD AK-1286 PO,DLT observation period: 21 days. Cohort 2: 2 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 3: 4 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 4: 5 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 5: 16 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 6: 24 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 7: 36 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 8: 50 mg/d BID AK-1286 PO,DLT observation period: 21 days.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Occurrence of drug limited toxicities (DLTs)	To assess by the occurrence of Drug Limited Toxicities (DLTs)	From Time of First dose through DLT observation period, 21 days
Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs)	To assess by the occurrence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Number of patients with changes in laboratory parameters from baseline	To assess safety of AK-1286	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Number of participants with changes in clinically significant vital sign from baseline	To assess safety of AK-1286	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Secondary Outcomes

Measure	Description	Time Frame
The overall response rate (ORR)	The overall response rate (ORR) will be estimated based on the proportion of evaluable patients whose overall response (ORR) during study treatment is CR or PR. Disease response will be assessed by the investigator using RECIST v1.1.response (ORR) during study treatment is CR or PR. Disease response will be assessed by the investigator using RECIST v1.1	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Age 18-75 years (including cut-off value), gender is not limited;
Patients with histologically or cytologically diagnosed advanced malignant solid tumors who have failed or are unable to tolerate standard treatment regimens with systemic standard therapy.
participants in the dose expansion phase must have quantifiable lesions according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1).
Anticipated minimum survival duration of 3 months.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Participants must meet the laboratory criteria.A. Bone marrow function needs to meet#ANC≥1.5×109/L#PLT≥100×109/L#Hb≥9g/dL B. renal function#Cr≤1.5 times the upper limit of normal value#or Creatinine clearance≥50ml/min C. liver function#total bilirubin<1.5 x ULN#For subjects with documented Gilbert syndrome,< 2.0 x ULN or subjects with indirect bilirubin levels suggesting a source of extrahepatic elevation<3.0 x ULN#ALT and AST≤ 2.5 x ULN#If liver metastasis occurs≤ 5 x ULN#D. Coagulation function#Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x upper normal limit (ULN), or international normalized ratio (INR) < 1.5 or within the target range (if preventive anticoagulant therapy is performed# E). The corrected QT interval (QTcF) of Fridericia method is less than 450 ms for males and less than 470 ms for females.
The elution period of macromolecular drugs is ≥ 4 weeks, and that of oral fluorouracil and small molecule targeted drugs is ≥ 2 weeks
Fertile women must have a negative blood pregnancy test within 7 days before receiving the first study drug;
For fertile men and women, they must be willing to use appropriate contraceptive methods 30 days before the first study drug administration and 120 days after the last study drug administration;
Did not participate in the clinical trial as a subject within 1 month before participating in the trial;
According to the judgment of the researcher, the compliance is high,willing to complete the test and can abide by the test scheme;
Voluntarily participate in this clinical trial, understand the research procedures and be able to sign the informed consent form in writing.

Exclusion Criteria:

Untreated patients with brain metastasis
Other malignant tumors in recent five years. Basal cell carcinoma of the skin, except squamous cell carcinoma of the skin or cervical carcinoma in situ after potential treatment;
Myocardial infarction, symptomatic congestive heart failure (New York Heart Association > grade II), unstable angina pectoris or arrhythmia requiring drug treatment occurred within 6 months before enrollment;
Have a history of gastrointestinal diseases or gastric surgery or inability to swallow oral drugs;
Active infection requiring treatment;
Patients with active hepatitis B (hepatitis B surface antigen and / or hepatitis B core antibody positive and HBV-DNA > 103 copies /mL or 200IU/mL) or hepatitis C patients (hepatitis C virus positive and / or HCV-RNA positive) or HIV positive patients are required to receive treatment.
Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks before the first use of the study drug, or elective surgery during the trial, or therapeutic or palliative radiotherapy within 2 weeks before the first use of the study drug;
Allergic constitution, or known history of allergy to this drug component;
According to the researchers' judgement, there are serious diseases that may endanger the safety of patients or affect the completion of research, such as uncontrollable hypertension, uncontrollable diabetes and thyroid diseases.
There is fluid accumulation in the third space that cannot be controlled by drainage or other methods (such as massive identification and hydrothorax)
Have a clear history of neurological or mental disorders；
The researchers believe that the subjects are not suitable to participate in this study for other reasons.